Clarivate PLC filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission on November 3, 2026, disclosing financial condition and operational updates for the third quarter of fiscal year 2026.
Key Highlights
- Share count: Clarivate reported 639,904,301 ordinary shares outstanding as of September 30, 2026.
- Exchange listing: The company's ordinary shares, of no par value, trade on the New York Stock Exchange under the symbol CLVT.
- Filer status: Clarivate is classified as a large accelerated filer, as indicated on the filing's cover page.
- Incorporation: The registrant is incorporated in Jersey, Channel Islands, with principal executive offices located at 70 St. Mary Axe, London, EC3A 8BE, United Kingdom.
- Life Sciences divestiture: The filing references a divestiture of Clarivate's Life Sciences and Healthcare business among items addressed in the company's forward-looking statements section.
- Value Creation Plan: The filing cites the company's ongoing Value Creation Plan as a factor discussed in forward-looking statements, alongside strategies related to artificial intelligence integration in products and services.
Clarivate PLC Q3 2026 Quarterly Disclosure: Shares, Structure, and Strategic Context
Clarivate PLC (NYSE:CLVT), a provider of information and analytics services incorporated in Jersey, Channel Islands, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, the company had 639,904,301 ordinary shares of no par value outstanding as of September 30, 2026. The registrant's principal executive offices are located at 70 St. Mary Axe, London, EC3A 8BE, United Kingdom.
The filing identifies Clarivate as a large accelerated filer, and confirms it is not a shell company, smaller reporting company, or emerging growth company. The company reported that it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such requirements for the past 90 days, according to the cover page disclosures.
In the cautionary note accompanying the quarterly report, the company identified several areas of forward-looking discussion, including the anticipated use of proceeds from the divestiture of its Life Sciences and Healthcare business, the progress of its Value Creation Plan, capital allocation plans and share repurchases, and the impact of artificial intelligence on its business and strategy. The filing states that these forward-looking statements "are based on available current market material and management's expectations, beliefs, and forecasts concerning future events." The company noted that it does not undertake any obligation to update or revise forward-looking statements except as may be required under applicable securities laws. The filing also identifies risks including the company's level of indebtedness, competition in its industry, ability to maintain high annual renewal rates, and data privacy and cybersecurity compliance obligations.
What Was Disclosed
Clarivate PLC submitted a Form 10-Q covering the quarter ended September 30, 2026, confirming 639,904,301 ordinary shares outstanding, large accelerated filer status, NYSE listing under CLVT, and referencing ongoing strategic items including a Life Sciences and Healthcare business divestiture and a Value Creation Plan.




Please wait processing your request...